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disorder, including reductions in total brain volume, mutant 
huntingtin (mHTT) protein aggregation, transcriptional dys-
regulation, and neurotransmitter receptor alterations (Davies 
et al., 1997; Cha et al., 1998; Luthi-Carter et al., 2000; Stack et al., 
2005). Critically, these pathological changes are accompanied by 
progressive motor and cognitive deficits (Menalled and Chesselet, 
2002; Levine et al., 2004) that closely mimic the human condition. 
Transgenic mouse models of HD can be sorted into two broad 
categories depending on whether they possess a fragment (e.g., 
exon 1) of the HTT gene or the full-length composition. Mouse 
strains from fragment models express only a truncated mHTT 
protein fraction and in vitro studies have demonstrated that this 
abbreviated fragment may be more toxic than the full-length pro-
tein (Hackam et al., 1998; Lunkes and Mandel, 1998). As such, 
fragment models typically exhibit an accelerated phenotype in 
comparison to full-length models that includes motor deficits, 
altered gait, hypoactivity, and weight loss (Carter et al., 1999). 
While fragment models display an HD-like phenotype, the obvi-
ous weakness is that they lack the natural genomic and protein 
context of the polyglutamine expansion. This raises the potential 
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Huntington’s disease (HD) is a genetically inherited neurodegen-
erative disorder that results in motor, cognitive, and psychiatric 
disturbances. One out of every 10,000 people is affected with the 
disorder and an even greater proportion remains at risk. HD is 
caused by a polyglutamine (CAG) trinucleotide repeat expansion 
in the IT-15 (HTT) gene, located on the short arm of chromosome 
4 (The Huntington’s Disease Collaborative Research Group, 1993). 
The mutation is autosomal dominant and onset occurs between 
30 and 50 years of age, although in a rare juvenile variant of the 
disease, symptoms can emerge as early as 5 years old. The severity 
of symptoms progressively worsens as a function of age and the 
illness is ultimately fatal (for review see Walker, 2007). No cure exists 
for HD, however, therapeutics that target the dopamine system 
have shown promise for managing the motor syndromes that are 
involved with the disorder (Bonelli and Wenning, 2006; Bonelli 
and Hofmann, 2007).
Since the discovery of the mutation in the HTT gene, several 
transgenic mouse models expressing the CAG repeat expansion 
have been developed which recapitulate characteristics of the 
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Huntington’s disease (HD) is characterized by numerous alterations within the corticostriatal 
circuitry. The striatum is innervated by a dense array of dopaminergic (DA) terminals and these 
DA synapses are critical to the proper execution of motor functions. As motor disturbances are 
prevalent in HD we examined DA neurotransmission in the striatum in transgenic (tg) murine 
models of HD. We used in vivo microdialysis to compare extracellular concentrations of striatal 
DA in both a fragment (R6/2) model, which displays a rapid and severe phenotype, and a full-
length (YAC128) model that expresses a more progressive phenotype. Extracellular striatal DA 
concentrations were significantly reduced in R6/2 mice and decreased concomitantly with 
age-dependent increasing motor impairments on the rotarod task (7, 9, and 11 weeks). In a 
sample of 11-week-old R6/2 mice, we also measured tissue concentrations of striatal DA and 
found that total levels of DA were significantly depleted. However, the loss of total DA content 
(<50%) was insufficient to account for the full extent of DA depletion in the extracellular fluid 
(ECF; ∼75%). We also observed a significant reduction in extracellular DA concentrations 
in the striatum of 7-month-old YAC128 mice. In a separate set of experiments, we applied 
d-amphetamine (AMPH; 10 μm) locally into the striatum to stimulate the release of intracellular 
DA into the ECF. The AMPH-induced increase in extracellular DA levels was significantly blunted 
in 9-week-old R6/2 mice. There also was a decrease in AMPH-stimulated DA efflux in 7-month-
old YAC128 mice in comparison to WT controls, although the effect was milder. In the same 
cohort of 7-month-old YAC128 mice we observed a significant reduction in the total locomotor 
activity in response to systemic AMPH (2 mg/kg). Our data demonstrate that extracellular DA 
release is attenuated in both a fragment and full-length tg mouse model of HD and support the 
concept of DA involvement in aspects of the syndrome.
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for alterations in protein dynamics and therefore necessitates the 
use of full-length models to investigate any resulting changes in 
disease features.
R6 transgenic mice are the most widely used strain derived from 
the fragment models and were the first established transgenic line 
in HD research. The most extensively characterized variant of 
this transgenic strain is the R6/2 line, which express the first of 67 
exons and carry a ∼160 CAG repeat expansion (Mangiarini et al., 
1996). These mice develop an aggressive HD-like phenotype that 
advances rapidly until the occurrence of spontaneous morbidity 
by 14–16 weeks of age (Carter et al., 1999). In contrast to the R6 
models, the YAC128 transgenic mouse model incorporates the 
entire HD gene, using a yeast artificial chromosome (YAC) vector 
system to express the full-length human HTT gene with a 128 CAG 
repeat expansion (Hodgson et al., 1999). The lifespan, as well as 
the progression of the HD-like phenotype in YAC128 mice is more 
prolonged than in R6/2 mice, with neuropathological and behav-
ioral abnormalities manifesting at later ages (Slow et al., 2003; Van 
Raamsdonk et al., 2007).
Evidence implicates abnormal nigrostriatal dopaminergic neu-
rotransmission in HD. In both human cases and animal models, 
early reductions in the striatal expression of dopamine receptors, 
attenuated receptor binding, and loss of the dopamine- and cAMP-
regulated phosphoprotein (DARPP-32) have been reported (Joyce 
et al., 1988; Sedvall et al., 1994; Cha et al., 1999; Bibb et al., 2000; 
Miller and Bezprozvanny, 2010). Reduced dopamine concentra-
tions in striatal tissue and the degeneration of nigrostriatal termi-
nals emerge in late stages of the disorder in both human cases and 
transgenic models of HD (Kish et al., 1987; Reynolds et al., 1999; 
Suzuki et al., 2001; Petersén et al., 2002). Additionally, studies utiliz-
ing striatal slice preparations have demonstrated that electrically 
evoked dopamine efflux is reduced in both R6/1 and R6/2 mice 
(Johnson et al., 2007; Ortiz et al., 2011; respectively), suggesting 
that dopamine release may be compromised in these models. As of 
yet, the synaptic release of dopamine has not been studied during 
awake, behaving conditions in transgenic mouse models of HD.
The goal of the present study was to examine, and compare 
where possible, nigrostriatal dopamine release dynamics in the 
fragment R6/2 and the full-length YAC128 mouse models of HD, 
using in vivo microdialysis. Both R6/2 and YAC128 mice develop 
deficits on the rotarod treadmill task and we measured the levels 
of striatal dopamine during these periods of motor dysfunction. 
As analogous neurophysiological abnormalities have been shown 
to exist across fragment and full-length transgenic models (for 
review see Cummings et al., 2010), we speculated that neurochemi-
cal abnormalities may also be a common feature of such models. 
Specifically, we hypothesized that extracellular striatal dopamine 
release would be attenuated in R6/2 and YAC128 mice in awake, 
behaving conditions concomitant with motor decline and as a func-
tion of age. In vitro studies have indicated that the intracellular 
storage of dopamine in nerve terminals may be compromised in 
HD as well and such a deficiency could contribute to deficits in 
extracellular dopamine release (Ortiz et al., 2010). In a separate set 
of experiments, we therefore measured the effects of amphetamine, 
a dopamine-releasing agent, on local striatal neurochemistry and 
on locomotor activity in order to investigate the integrity of intra-
cellular dopamine stores in R6/2 and YAC128 mice.
EXPERIMENTAL PROCEDURES
ANIMALS
Transgenic male mice expressing a truncated human HTT gene 
with a 160 ± 10 CAG repeat expansion (R6/2) or a full-length 
human HTT gene with a 128 CAG repeat expansion (YAC128) 
in exon 1 and their respective wild-type controls were obtained 
from Jackson Laboratories (Bar Harbor, ME, USA). Animals were 
housed individually in plastic microisolator cages with food and 
water available ad libitum. Animals were kept under conditions of 
constant temperature (21°C) and humidity (40%) and maintained 
on a 12-h light/dark cycle (lights on from 7:00 am to 7:00 pm). All 
efforts were made to minimize animal suffering and to limit the 
number of animals utilized for these experiments. Animal proce-
dures were conducted in accordance with the National Institutes 
of Health Guide for the Care and Use of Laboratory Animals and 
were approved by Rutgers University Institutional Animal Care 
and Use Committee.
MOTOR PhENOTyPE
Motor coordination was assessed using an Economex rotarod appa-
ratus (Columbus Instruments, Columbus, OH, USA). R6/2 mice 
and wild-type controls were trained on the rotarod treadmill task 
at 10 rpm for three consecutive trials (60 s maximum duration) 
1 day prior to testing. The following day, mice were tested at five 
fixed speeds (5, 10, 15, 20, 25 rpm) for two separate trials. Fall 
latency (s) at each speed was averaged across trials and used for 
statistical comparison. Testing was carried out at 7, 9, and 11 weeks 
in separate groups of R6/2 mice and 7 months in YAC128 mice and 
their respective wild-type controls.
MICRODIALySIS PROCEDURE
Microdialysis probes were of a vertical, concentric design, simi-
lar to that previously described in our laboratory (Cobb and 
Abercrombie, 2002). Probes were constructed such that the probe 
inlet consisted of a piece of PE-10 tubing (Clay Adams, Parsippany, 
NJ, USA) and a piece of fused silica capillary tubing (I.D. 75 μm and 
O.D. 150 μm; Polymicro Technologies, Phoenix, AZ, USA) served as 
the outlet. A semi-permeable microdialysis membrane (molecular 
weight cut-off = 13 kD; O.D. = 216 μm; Spectrum Laboratories, 
Rancho Dominguez, CA, USA) was placed over the end of the 
exposed silica tubing, glued to the PE-10 tubing and coated with a 
thin epoxy layer, leaving a 2-mm long active exchange area at the 
end of the probe. Probes were continuously perfused with artifi-
cial cerebrospinal fluid (aCSF; NaCl 147 mM, KCl 2.5 mM, CaCl
2
 
1.3 mM, MgCl
2
 0.9 mM, pH 7.4) using a microliter infusion pump 
(Harvard Apparatus, Holliston, MA, USA) at a flow rate of 1.5 μl/
min. Prior to implantation, probes were calibrated in vitro to deter-
mine their relative recovery rates. Only probes with recovery rates 
between 10 and 15% were used.
R6/2 mice and their wild-type controls were anesthetized with 
40–50 mg/kg pentobarbital and 250 mg/kg chloral hydrate (i.p.). 
YAC128 mice and their wild-type controls were anesthetized with 
80–100 mg/kg ketamine and 10 mg/kg xylazine (i.p.). The mice were 
placed into a stereotaxic frame (David Kopf Instruments, Tujunga, 
CA, USA) and onto a heating pad to prevent hypothermia. With 
the skull flat, the microdialysis probe was implanted into the stria-
tum at the following coordinates: AP: +0.5 mm, ML: ±1.95 mm 
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their respective wild-type controls. All experiments involving the 
local application of amphetamine were conducted 48 h after probe 
implantation.
In experiments involving systemic administration of d-amphet-
amine (2 mg/kg, i.p.), the drug was dissolved in sterile 0.9% saline 
vehicle. The effect of systemic amphetamine on locomotor activity 
was investigated in 7-month-old YAC128 mice and their wild-type 
controls. Prior to testing, mice were untethered and the polyeth-
ylene tubing emanating from the probes was clipped so that only 
the acrylic head cap remained. Mice were allowed to habituate in 
their home cages with this new arrangement for at least 1 week 
preceding amphetamine treatment. Based on qualitative observa-
tions, animals showed no signs of impairment due to either the 
surgery or the presence of head caps. One day prior to amphetamine 
administration, mice were habituated to plastic open field chambers 
(51 cm × 32 cm × 20 cm) overnight. Following habituation, mice 
were administered drug and spontaneous locomotor activity was 
monitored for 60 min via automated activity chambers equipped 
with infrared photobeams (Flexfield, San Diego Instruments, Inc., 
San Diego, CA, USA).
DATA ANALySIS
Data are presented as mean ± SEM. Dialysate values represent pico-
grams per 20 μl microdialysis sample. Factorial ANOVA was used 
to assess main effect in each data set examined. Data then were 
subdivided according to the interactions found in the global test 
and separate lower order analyses carried out. Where appropriate, 
the Bonferroni post hoc test was used for multiple comparisons. 
Differences were considered statistically significant when p < 0.05.
hISTOLOgy
Upon completion of each experiment, animals were administered 
a lethal dose of sodium pentobarbital and were perfused intra-
cardially with 0.9% saline followed by 10% formaldehyde. Brains 
were extracted and post-fixed in fresh fixative overnight at 4°C and 
transferred to 30% sucrose in phosphate buffer solution overnight 
at 4°C for cryoprotection. Coronal sections of 50 μm thickness 
were obtained from striata and stained with Cresyl Violet to verify 
probe placement in the striatum. A representative histological sec-
tion showing a microdialysis probe track in the mouse striatum is 
shown in Figure 1.
MATERIALS
Ketamine was purchased from Phoenix Pharmaceutical Inc. (St. 
Joseph, MO, USA). Xylazine, chloral hydrate, sodium pentobarbital, 
and d-amphetamine were purchased from Sigma (St. Louis, MO, 
USA). All other reagents and chemicals were of the highest purity 
commercially available (Fisher Scientific, Suwanee, GA, USA).
RESULTS
ROTAROD ASSESSMENT IN R6/2 AND yAC128 MICE
Performance on a fixed speed rotarod paradigm was assessed 
in R6/2, YAC128 mice and their respective wild-type controls 
(Figure 2A). Mice were placed on an elevated, rotating plat-
form for a maximum of 60 s and the latency that it took for 
each to fall off was measured at 5, 10, 15, 20, and 25 rpm. The 
latency to stay on the rotating platform was significantly reduced 
relative to bregma and DV: −4.0 mm from dura (Franklin and 
Paxinos, 2008). Probes were anchored to the skull by two small 
screws (Small Parts, Miami Lakes, FL, USA) and dental cement. The 
probe inlet and outlet lines were then fed through a metal tether that 
attached to the head-post at one end, and to a single-channel fluid 
swivel (Instech Laboratories, Plymouth Meeting, PA, USA) at the 
other end. The mice were allowed to recover for at least 18 h before 
experiments began. Post-operative care consisted of administering 
lactated Ringer’s solution (1.0–2.0 ml/30 g body weight, s.c.) and 
placing the animal under a heat lamp for 1–3 h after surgery. All 
microdialysis experiments were conducted during the light portion 
of the diurnal cycle.
DOPAMINE QUANTIfICATION
Microdialysis experiments were conducted in round plastic test 
chambers (14 cm × 20 cm) equipped with a counter-balanced 
arm and a swivel assembly (Instech, Plymouth Meeting, PA, USA). 
The HPLC–EC system consisted of an injector (Rheodyne, Cotati, 
CA, USA), a VeloSep RP-18 column (100 × 3.2 mm; PerkinElmer, 
Waltham, MA, USA) and a Shimadzu LC-10AD VP solvent deliv-
ery pump (Shimadzu Scientific Instruments, Inc., Columbia, MD, 
USA), that delivered the mobile phase at a flow rate of 0.7 ml/min. 
The mobile phase was composed of 0.1 M sodium acetate buffer 
(pH 4.2), 0.1 mM EDTA, 1.2 mM sodium octyl sulfate, and 8% (v/v) 
methanol. An electrochemical detector (Coulochem II; ESA Inc., 
Chelmsford, MA, USA) with a flow cell electrode set at an applied 
potential of +260 mV was used. The detector output was con-
nected to a computerized data acquisition system (PowerChrom, 
Denistone East, NSW, Australia). Dopamine and 3,4-dihydroxy-
phenylacetic acid (DOPAC) were identified by retention time and 
quantified based on peak height relative to the peak height of a 
10-nM standard prepared in 0.1 M perchloric acid that was made 
up fresh daily.
A separate cohort of 11-week-old R6/2 mice and their wild-type 
controls were sacrificed by decapitation and the striata were rapidly 
dissected on ice, wrapped in aluminum foil, labeled, and frozen at 
−80°C until analysis. The weight of each striatum was measured and 
then tissue was homogenized in 0.1 M perchloric acid containing 
100 μM EDTA (20 μl/mg wet tissue weight). Homogenates were 
centrifuged at 29,200 g for 25 min at 2–8°C. The amount of dopa-
mine in 20 μl samples of the resulting supernatant was quantified 
by HPLC–EC using the protocol described above for the analysis 
of dopamine in dialysate samples.
EXPERIMENTAL PROCEDURES
Prior to pharmacological manipulations, baseline dialysate sam-
ples were assayed for dopamine until three consecutive samples 
differed by less than 15%. In experiments involving the local 
application of d-amphetamine into the striatum via reverse 
microdialysis, a glass syringe containing a 10-μM solution of 
amphetamine dissolved in aCSF was connected to the inlet of 
the probe following the initial baseline determination. Collection 
of dialysate samples resumed 15 min later to allow for the fluid 
to flow through the probe and equilibrate to the drug solution. 
Samples were collected every 10 min for a 60-min duration. The 
effect of local amphetamine on extracellular dopamine was inves-
tigated in 9-week-old R6/2 mice, 7-month-old YAC128 mice and 
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7-month-old YAC128 mice compared to age-matched wild-type 
controls [F (1, 56) = 11.88; p < 0.01; Figure 2B]. Post hoc tests 
indicated that 7-month-old YAC128 mice fell at significantly 
shorter latencies than wild-type controls at every speed faster 
than 5 rpm. Data are only presented in graphical form for 10 
and 20 rpm as these speeds are most representative of overall 
performance in both genotypes.
EXTRACELLULAR STRIATAL DOPAMINE AND DOPAC CONCENTRATIONS
R6/2 mice
Extracellular striatal dopamine was significantly attenuated as a 
function of genotype [F (1, 34) = 46.96; p < 0.0001; Figure 3A]. 
Post hoc tests revealed that there was a significant reduction in 
extracellular dopamine in R6/2 mice and levels were diminished 
at 7 weeks (WT: 8.4 ± 0.9 pg/20 μl; R6/2: 5.6 ± 0.6 pg/20 μl), 
9 weeks (WT: 8.1 ± 1.4 pg/20 μl; R6/2: 3.3 ± 0.7 pg/20 μl), and 
11 weeks of age (WT: 11.4 ± 1.2 pg/20 μl; R6/2: 2.7 ± 0.5 pg/20 μl). 
One-way ANOVA indicated that extracellular levels of striatal 
dopamine significantly decreased in R6/2 mice as a function of 
age [F (2, 17) = 6.812; p < 0.01]. Specifically, post hoc tests dem-
onstrated that extracellular dopamine was significantly reduced 
in 9- and 11-week old R6/2 mice in comparison to 7-week-old 
R6/2 mice. There was no change in striatal extracellular dopa-
mine concentrations as a function of age in wild-type controls 
[F (2, 17) = 2.303; n.s.]. Extracellular striatal DOPAC was signifi-
cantly attenuated as a function of genotype [F (1, 34) = 50.96; 
p < 0.0001; Figure 3B]. Post hoc tests indicated that although 
extracellular concentrations of striatal DOPAC were not sig-
nificantly different at 7 weeks (WT: 1569 ± 137 pg/20 μl; R6/2: 
1191 ± 114 pg/20 μl) they were significantly reduced by 9 weeks 
(WT: 1589 ± 127 pg/20 μl; R6/2: 647 ± 122 pg/20 μl) and 11 weeks 
of age (WT: 1544 ± 191 pg/20 μl; R6/2: 503 ± 453 pg/20 μl) in R6/2 
mice in comparison to wild-type controls. A one-way ANOVA 
revealed that extracellular DOPAC significantly decreased in R6/2 
mice as a function of age [F (2, 17) = 15.32; p < 0.001]. There was 
no change in extracellular DOPAC amounts as a function of age 
in wild-type controls [F (2, 17) = 0.20; n.s.].
Figure 1 | Photomicrograph of Nissl-stained histological section 
demonstrating representative microdialysis probe placement with a 
2-mm active area in mouse striatum. AC, anterior commissure; EC, external 
capsule.
Figure 2 | rotarod performance in (A) r6/2 transgenic mice (7 weeks, n = 22 WT, 23 r6/2; 9 weeks, n = 15 WT, 13 r6/2; 11 weeks, n = 14 WT, 6 r6/2) and (B) 
7-month-old YAC128 transgenic mice (n = 7 WT, 9 YAC128). All data are mean ± SEM. * Indicates significantly different from WT, p < 0.05; ** indicates p < 0.001; 
*** indicates p < 0.005; +, ++ R6/2 week 7 vs. weeks 9 and 11 (p < 0.05, 0.01, respectively).
as a function of genotype in 7-week-old [F (1, 172) = 18.78; 
p < 0.0001), 9-week-old [F (1, 104) = 50.84; p < 0.0001], and 
11-week-old [F (1, 72) = 98.22; p < 0.0001] R6/2 mice compared 
to wild-type controls. Post hoc tests revealed that R6/2 mice fell 
off the rotarod at significantly shorter latencies than wild-type 
controls at every speed across all ages tested. One-way ANOVA 
tests showed that the latency to remain on the rotating plat-
form significantly decreased as a function of age in R6/2 mice 
[F (2, 39) = 8.074; p < 0.01] but not in wild-type controls [F (2, 
48) = 2.013; n.s.]. The latency to stay on the rotating platform 
also was significantly diminished as a function of genotype in 
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EffECT Of LOCAL STRIATAL AMPhETAMINE (10 μM) APPLICATION ON 
EXTRACELLULAR DOPAMINE CONCENTRATIONS
R6/2 mice
Local amphetamine induced a significant increase in extracellular dopa-
mine levels across time [F (6, 24) = 75.42; p < 0.0001]. The amphetamine 
induced increase in dopamine efflux was significantly attenuated as 
a function of genotype [F (1,24) = 42.25; p < 0.01; Figure 6A]. Post 
hoc tests indicated that amphetamine induced dopamine release was 
significantly diminished in 9-week-old R6/2 mice in comparison to 
wild-type controls at all time intervals measured. The maximum peak 
response in amphetamine induced dopamine efflux was significantly 
diminished in 9-week-old R6/2 mice (38.9 ± 7.4 pg/20 μl) vs. wild-type 
controls (114.4 ± 10.7 pg/20 μl) [t (4) = 5.82; p < 0.01; Figure 6B].
YAC128 mice
Local amphetamine induced a significant increase in extracellular 
dopamine across time [F (6, 72) = 23.04; p < 0.0001; Figure 7A]. 
Although amphetamine induced dopamine efflux was diminished 
In the 11-week-old cohort, striatal tissue concentrations of 
dopamine were measured in R6/2 mice and wild-type controls 
(Figure 4A). R6/2 mice exhibited a significant abatement in stri-
atal tissue dopamine content (5478 ± 487 pg/20 μl) in compari-
son to wild-type controls (10680 ± 833 pg/20 μl) [t (10) = 5.39; 
p < 0.001]. The reduction in striatal tissue content of dopamine 
(47%) was not as dramatic as the reduction in striatal extracel-
lular concentrations of dopamine (76%) in 11-week-old R6/2 
mice (Figure 4B).
YAC128 mice
Extracellular dopamine concentrations in 7-month-old YAC128 
mice were significantly reduced (5.0 ± 1.4 pg/20 μl) in compari-
son to wild-type controls (10.5 ± 1.9 pg/20 μl) [t (14) = 2.39; 
p < 0.05; Figure 5A]. Although extracellular DOPAC levels were 
slightly lower in 7-month-old YAC128 mice (1834 ± 245 pg/20 μl), 
there was no significant difference between wild-type controls 
(2358 ± 299 pg/20 μl) [t (14) = 1.37; n.s.; Figure 5B].
Figure 3 | In vivo microdialysis measurements of basal levels of extracellular (A) dopamine and (B) DOPAC in striatum of r6/2 transgenic mice (7 weeks, 
n = 6 WT, 6 r6/2; 9 weeks, n = 6 WT, 6 r6/2; 11 weeks, n = 8 WT, 8 r6/2). Data are picograms per 20 μl sample. All data are mean ± SEM. * Indicates significantly 
different from WT, p < 0.05; ** indicates p < 0.001; *** indicates p < 0.005; +, ++ R6/2 week 7 vs. weeks 9 and 11 (p < 0.05, 0.01, respectively).
Figure 4 | Dopamine content in (A) striatal tissue of 11-week-old r6/2 transgenic mice (n = 6 WT, 6 r6/2) and (B) comparison of the percentage of 
dopamine levels in relation to WT mice in tissue and the extracellular fluid (eCF). Striatal tissue dopamine content data are μg/g wet weight of tissue and 
striatal ECF dopamine data are picograms per 20 μl sample of dialysate. All data are mean ± SEM. *** Indicates significantly different from WT, P < 0.005.
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Figure 5 | In vivo microdialysis measurements of basal levels of extracellular (A) dopamine and (B) DOPAC in striatum of 7-month-old YAC128 mice (n = 7 
WT, 9 YAC128). Data are picograms per 20 μl sample. All data are mean ± SEM. * Indicates significantly different from WT, p < 0.05.
Figure 6 | effect of intrastriatal application of amphetamine (10 μM) on striatal (A) dopamine release and the (B) maximum peak increase in dopamine 
efflux in 9-week-old r6/2 transgenic mice (n = 3 WT, 3 r6/2). Presence of amphetamine in perfusate is indicated by black bar. Data are picograms per 20 μl 
sample. All data are mean ± SEM. * Indicates significantly different from WT, P < 0.05; ** indicates P < 0.001; *** indicates P < 0.005.
Figure 7 | effect of intrastriatal application of amphetamine (10 μM) on striatal (A) dopamine release and the (B) maximum peak increase in dopamine 
efflux in 7-month-old YAC128 transgenic mice (n = 5 WT, 9 YAC128). Presence of amphetamine in perfusate is indicated by black bar. Data are picograms per 20 μl 
sample. All data are mean ± SEM. * Indicates significantly different from WT, P < 0.05; ** indicates P < 0.001; *** indicates P < 0.005.
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et al., 2009). In the present studies, significant impairments in the 
rotarod assay were apparent in R6/2 and YAC128 mice, with rotarod 
performance being roughly comparable at 7 weeks and 7 months of 
age, respectively. In both R6/2 and YAC128 mice, decline in motor 
function were associated with a significant reduction in the levels 
of extracellular striatal dopamine. Interestingly, while the 7-month 
age point in YAC128 mice is characterized by motor disturbances, 
blunt neurodegeneration does not emerge until older ages (Slow 
et al., 2003) suggesting the presence of alternative pathological 
alterations. Motor performance and striatal dopamine release were 
further assessed in R6/2 mice at 9 and 11 weeks of age, with both 
measures progressively diminishing as a function of group time 
point. Masuzawa et al. (2003) demonstrated that pentobarbital can 
attenuate dopamine release and while we used this compound as 
a general anesthetic during surgical procedures, all experiments 
took place at least 18 h subsequent to surgery making it unlikely 
that there was an interaction between anesthesia and extracellular 
dopamine at the time experiments were conducted. Taken together, 
these findings lend support to the notion that alterations in syn-
aptic function, including reduced levels of extracellular dopamine, 
may contribute to the disease phenotype across different transgenic 
mouse models of HD. Indeed, a wide range of dopamine related 
abnormalities have been reported, including dopamine receptor 
sensitization, attenuated striatal dopamine-dependent plasticity 
and altered dopamine-dependent modulation of corticostriatal 
currents, that may reflect the attenuated extracellular dopamine 
concentrations presently reported (Pineda et al., 2005; Cummings 
et al., 2006; Kung et al., 2007; André et al., 2011).
In addition to extracellular dopamine concentrations, dopamine 
content in striatal tissue was assessed in 11-week old R6/2 mice. 
In agreement with previous reports (Reynolds et al., 1999; Mochel 
et al., 2011), it was found that striatal tissue levels of dopamine 
were reduced by roughly half, relative to wild-type control animals. 
Importantly, reductions in tissue concentrations of dopamine were 
not as severe as the reductions observed in the extracellular fluid 
(ECF; 45 vs. 75% reduction, respectively), suggesting the presence 
of an available intracellular pool of dopamine that is not being 
adequately utilized under spontaneous in vivo conditions. This 
in 7-month-old YAC128 mice in comparison to wild-type con-
trols, there was no significant effect of genotype [F (1, 72) = 1.93, 
n.s.]. Similarly, while the maximum peak response in ampheta-
mine induced dopamine release was diminished in 7-month-
old YAC128 mice (31.8 ± 9.6 pg/20 μl) vs. wild-type controls 
(50.2 ± 12.0 pg/20 μl) the effect was not significant [t (12) = 1.18; 
n.s.; Figure 7B].
In 7-month-old YAC128 mice, the effect of systemic ampheta-
mine (2 mg/kg, i.p.) on spontaneous locomotor activity was inves-
tigated. There was no significant difference in the basal activity 
counts between genotypes in 7-month-old YAC128 mice and 
wild-type controls [t (9) = 0.39; n.s.; Figure 8A]. Amphetamine 
induced a significant increase in locomotor activity across time [F 
(6, 54) = 0.96; p < 0.05]. Although amphetamine induced loco-
motor activity was diminished in 7-month-old YAC128 mice in 
comparison to wild-type controls, there was no significant effect of 
genotype [F (1, 54) = 3.80, n.s.]. Collapsing the locomotor counts 
across all time bins revealed that the total activity in response to 
amphetamine over 60 min post-drug was significantly attenuated 
in 7-month-old YAC128 mice vs. wild-type controls [t (9) = 1.88; 
p < 0.05; Figure 8B].
DISCUSSION
The present studies utilized in vivo microdialysis to assess striatal 
dopamine release dynamics in two transgenic mouse models of HD. 
We report that the concentrations of extracellular striatal dopa-
mine are reduced in R6/2 and YAC128 transgenic mice relative to 
their respective wild-type controls. These data are consistent with 
previous studies demonstrating alterations in nigrostriatal func-
tion in both animal models and human cases of HD (e.g., Kish 
et al., 1987; Petersén et al., 2002; Johnson et al., 2006; Ortiz et al., 
2011). Importantly, the present studies extend these findings and 
represent the first demonstration of attenuated striatal dopamine 
release across transgenic mouse models of HD constructed using 
different genetic approaches.
Performance deficits on the rotarod treadmill task are reliably 
documented across multiple HD transgenic strains, including R6/2 
and YAC128 mice (Carter et al., 1999; Slow et al., 2003; Menalled 
Figure 8 | effect of systemic injection of amphetamine (2 mg/kg; injection indicated by arrow) on (A) 10 min bins of locomotor activity and (B) the total 
beam break counts during a 60-min period in 7-month-old YAC128 transgenic mice (n = 5 WT, 6 YAC128). * Indicates significantly different from WT, P < 0.05.
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The local application of amphetamine into the striatum 
produced an increase in extracellular dopamine release in both 
9-week-old R6/2 mice and 7-month-old YAC128 mice, as well as 
in their respective wild-type controls. However, overall dopamine 
efflux was significantly attenuated across all time points in R6/2 
mice and considerably reduced in 7-month-old YAC128 mice, 
although this effect fell short of significance. Similarly, the maxi-
mal effect of amphetamine on dopamine release was attenuated in 
both R6/2 and YAC128 mice (66 and 37% reductions, respectively). 
It should be noted that amphetamine-stimulated dopamine levels 
were considerably lower in the wild-type controls for the YAC128 
mice, compared to those for the R6/2 mice. It is plausible that 
the different background strains and/or the divergent ages of the 
respective wild-type mice (7 months vs. 9 weeks) may account 
for the differences in amphetamine-stimulated dopamine release. 
Alternatively, it is possible that cytosolic pools of dopamine in 
7-month-old YAC128 mice are not as depleted as in 9-week-old 
R6/2 mice. In any case, further experimentation at different age 
points, both younger and older, is necessary to fully delineate 
the progression of changes in dopamine release dynamics in the 
extended phenotype YAC128 mice.
In addition to the effect of local amphetamine on striatal dopa-
mine release, the effect of systemic amphetamine on locomotor 
activity was assessed in the same cohort of 7-month-old YAC128 
mice after a 1-week drug washout period. Phenotype progres-
sion is too rapid to challenge the same cohort of R6/2 mice to 
systemic amphetamine after an extended washout period and as 
such these experiments were only performed in YAC128 mice. 
Overall, there was a significant effect of genotype on locomotion, 
with YAC128 mice showing significantly reduced amphetamine-
induced locomotion. This finding is consistent with decreased 
amphetamine-stimulated dopamine release and parallels a study 
in which amphetamine-induced locomotor activity was reduced 
in R6/2 mice (Hickey et al., 2002). These data lend support to the 
notion that cytosolic dopamine is attenuated in R6/2 and YAC128 
mice and may contribute to the deficits in extracellular dopamine 
concentrations that we report.
Reductions in cytosolic dopamine levels could be caused by 
either deficits in the production of newly synthesized dopamine or 
the loss of nigrostriatal terminals. In light of the fact that tyrosine 
hydroxylase (TH) is the rate-limiting enzyme in the biosynthetic 
pathway for the production of dopamine, Yohrling et al. (2003) 
demonstrated a significant reduction in TH activity in the striatum 
of 12 week-old-R6/2 mice, raising the possibility that deficits in 
dopamine synthesis may underlie depleted cytosolic concentra-
tions. Alternatively, accumulating evidence indicates that the deple-
tion of dopamine may be the result of nigrostriatal degeneration 
that manifests in an age-dependent manner. In 16-week-old R6/1 
mice there is no difference in the number of nigrostriatal projec-
tions or the number of dopamine neurons within the substantia 
nigra pars compacta (Petersén et al., 2002). By 30 weeks, however, 
nigrostriatal projections are decreased and the total number of 
cells within the SNc is reduced (Pineda et al., 2005; Rubio et al., 
2009). Interestingly, neurons within the SNc of 16-week-old R6/1 
mice were diminished in size and exhibited mHTT aggregate 
bodies, suggesting that these pathological abnormalities may pre-
cede blunt degeneration within this area (Petersén et al., 2002). 
finding is particularly intriguing when viewed in the context of 
animal models of Parkinson’s disease (PD) in which the opposite 
pattern emerges. In PD models, tissue levels of dopamine must 
be depleted by greater than 80% in order for deficits in extracel-
lular dopamine release to emerge (Abercrombie et al., 1990). The 
loss of tissue dopamine content and reductions in the density of 
postsynaptic dopamine receptors has been reported extensively 
in HD, however, this finding accentuates the need to account for 
presynaptic release deficits in HD pathogenesis as well.
There are multiple factors that could contribute to exocytotic 
release dysfunctions in HD. Several synaptic proteins that are 
involved in exocytotic processes, including complexin II, snare com-
plex, synaptobrevin 2 and rab3a, have been shown to be abnormal 
in both transgenic mouse models and human cases of HD (Morton 
et al., 2001; Freeman and Morton, 2004; Glynn et al., 2007). In line 
with our results, Morton and Edwardson (2001) demonstrated that 
there was a progressive decline in complexin II from 7 weeks onward 
in R6/2 mice. Another potential mechanism may involve altera-
tions in calcium homeostasis and signaling, which could lead to 
changes in vesicular release probabilities (Bibb et al., 2000; Hansson 
et al., 2001). Moreover, the mHTT protein also disrupts vesicular 
transport and such an abnormality could alter vesicular pool sizes 
(Velier et al., 1998). Indeed, Ortiz et al. (2010) demonstrated that 
storage vesicles in acute nigrostriatal slices are significantly dimin-
ished in R6/2 mice.
Intriguingly, the concentrations of extracellular striatal DOPAC 
(the main catabolite of dopamine) were significantly decreased 
in R6/2 mice and showed a tendency to be decreased in YAC128 
mice, although this effect was not significant. Extracellular DOPAC 
derives from, and reflects the metabolism of, newly synthesized 
dopamine in the cytosol (Zetterström et al., 1988; Yadid et al., 2000). 
In the present studies, the observation of diminished amounts of 
striatal DOPAC coupled to the finding that tissue levels of striatal 
dopamine are reduced lends support to the possibility that cytosolic 
dopamine pools are depleted as well in transgenic mouse models 
of HD.
In order to more directly quantify cytosolic dopamine con-
centrations, we examined the effect of intrastiatal application of 
amphetamine on striatal dopamine efflux via reverse microdialysis. 
Amphetamine is a psychostimulant that promotes the release of 
newly synthesized dopamine from cytosolic pools into the ECF via 
an impulse-independent, exchange diffusion method and selec-
tive inhibition of the dopamine transporter (Fischer and Cho, 
1979). Previous work has confirmed the mechanism of action of 
amphetamine by demonstrating that its stimulant properties are 
abolished (except at very high doses) with the pretreatment of 
alpha-methyl-para-tyrosine (AMPT), a compound that inhibits 
the synthesis of dopamine in the cytosol, but not by reserpine, 
which depletes dopamine stored in vesicles (Chiueh and Moore, 
1974; Niddam et al., 1985; Parker and Cubeddu, 1986; Callaway 
et al., 1989; Heeringa and Abercrombie, 1995). Alterations in the 
levels and/or kinetics of the dopamine transporter could obscure 
the comparisons between genotypes, however, Petersén et al. (2002) 
demonstrated that the expression patterns of striatal dopamine 
transporters were comparable and correspondingly Johnson et al. 
(2006) exhibited that uptake through the dopamine transporter 
was similar between R6/2 and wild-type controls.
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